Introduction The efficacy and safety profile of ustekinumab (UST) in Crohn's disease (CD) is
favorable; however, data in elderly patients are lacking. We aimed to assess the safety and …

Background: The choice between infliximab (IFX) and vedolizumab (VED) as a first-line
biological agent in moderate-to-severe ulcerative colitis (UC) can be difficult. Second-line …

Abstract Background and Aims Despite intravenous (IV) vedolizumab being established for
treatment of inflammatory bowel disease (IBD), the novel subcutaneous (SC) route of …

There are no prospective, head-to-head, controlled trials comparing the efficacy and safety
of Infliximab (IFX) and Vedolizumab (VDZ) for the treatment of moderate-to-severe ulcerative …

Background: Prospectively and systematically collected real-world data on vedolizumab are
scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in …

Abstract Purpose of Review Treating moderate-to-severe inflammatory bowel disease has
become increasingly complex as the array of available biologics increases. Moreover …

Abstract Background & Aims Vedolizumab is an anti-a4b7 monoclonal antibody that is
licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis. The …

Ulcerative colitis (UC), a chronic, relapsing, remitting disease of the colon and rectum, is
characterized by inflammatory ulceration of the mucosa. Current UC therapy relies on …

Abstract Background and Objectives Vedolizumab has demonstrated efficacy and safety in
patients with Crohn's disease [CD] and ulcerative colitis [UC]. Endoscopic outcome data are …

BACKGROUND Remarkable progress over the last decade has equipped clinicians with
many options in the treatment of inflammatory bowel disease. Clinicians now have the …